Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsIn this open-label, single-arm Phase I/II trial, 87 patients with recurrent/refractory non-Hodgkin lymphoma received an infusion at doses of 0.5 × 106–8 × 106 TanCAR7 T cells per kilogram of body weight after conditioning chemotherapy.
[Leukemia]
6445218 PTLWYCDY items 1 apa 0 default asc 1 164685 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-1e781ccd12deef58f94a3b8482055a1c%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22PTLWYCDY%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EZhang%2C%20Y.%2C%20Wang%2C%20Y.%2C%20Liu%2C%20Y.%2C%20Tong%2C%20C.%2C%20Wang%2C%20C.%2C%20Guo%2C%20Y.%2C%20Ti%2C%20D.%2C%20Yang%2C%20Q.%2C%20Qiao%2C%20S.%2C%20Wu%2C%20Z.%2C%20%26amp%3B%20Han%2C%20W.%20%282021%29.%20Long-term%20activity%20of%20tandem%20CD19%5C%2FCD20%20CAR%20therapy%20in%20refractory%5C%2Frelapsed%20B-cell%20lymphoma%3A%20a%20single-arm%2C%20phase%201%26%23x2013%3B2%20trial.%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2C%201%26%23x2013%3B8.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-021-01345-8%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-021-01345-8%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3DPTLWYCDY%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20activity%20of%20tandem%20CD19%5C%2FCD20%20CAR%20therapy%20in%20refractory%5C%2Frelapsed%20B-cell%20lymphoma%3A%20a%20single-arm%2C%20phase%201%5Cu20132%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yajing%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yao%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chuan%22%2C%22lastName%22%3A%22Tong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chunmeng%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yelei%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dongdong%22%2C%22lastName%22%3A%22Ti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qingming%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shen%22%2C%22lastName%22%3A%22Qiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhiqiang%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Weidong%22%2C%22lastName%22%3A%22Han%22%7D%5D%2C%22abstractNote%22%3A%22Increasing%20the%20remission%20rate%20and%20reducing%20the%20recurrence%20rate%20can%20improve%20the%20clinical%20efficacy%20of%20chimeric%20antigen%20receptor%20%28CAR%29%20T%20cell%20therapy%20in%20recurrent%5C%2Frefractory%20non-Hodgkin%20lymphoma%20%28r%5C%2FrNHL%29.%20In%20this%20open-label%2C%20single-arm%20phase%20I%5C%2FII%20trial%2C%2087%20patients%20with%20r%5C%2FrNHL%2C%20including%2058%20patients%20with%20aggressive%20diffuse%20large%20B-cell%20lymphoma%20and%2024%20with%20high%20tumour%20burden%2C%20received%20an%20infusion%20at%20doses%20of%200.5%5Cu2009%5Cu00d7%5Cu2009106%5Cu20138%5Cu2009%5Cu00d7%5Cu2009106%20TanCAR7%20T%20cells%20per%20kilogram%20of%20body%20weight%20after%20conditioning%20chemotherapy.%20The%20best%20overall%20response%20rate%20was%2078%25%20%2895%25%20confidence%20interval%20%5BCI%5D%2C%2068%5Cu201386%29%3B%20response%20rates%20were%20consistent%20across%20prognostic%20subgroups.%20The%20median%20follow-up%20was%2027.7%20months.%20The%20median%20progression-free%20survival%20was%2027.6%20months%20%2895%25%20CI%2C%2011%20to%20not%20reached%29.%20Cytokine%20release%20syndrome%20%28CRS%29%20occurred%20in%2061%20patients%20%2870%25%29%20with%2060%25%20of%20cases%20being%20grade%201%20or%202%20and%2010%25%20being%20grade%203%20or%20greater.%20Grade%203%20CAR%20T%20cell-related%20encephalopathy%20syndrome%20%28CRES%29%20occurred%20in%202%20patients%20%282%25%29.%20Two%20patients%20died%20from%20treatment-associated%20severe%20pulmonary%20infection%2C%20and%20one%20died%20from%20CRS-related%20pulmonary%20injury%20between%201%20and%203%20months%20post%20infusion.%20Long-term%20remissions%20were%20observed%20following%20the%20use%20of%20TanCAR7%20T%20cells%20in%20r%5C%2FrNHL%20with%20a%20safety%20profile%20that%20included%20CRS%20but%20few%20cases%20of%20CRES.%22%2C%22date%22%3A%222021-07-16%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-021-01345-8%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41375-021-01345-8%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-07-16T18%3A27%3A40Z%22%7D%7D%5D%7D
Zhang, Y., Wang, Y., Liu, Y., Tong, C., Wang, C., Guo, Y., Ti, D., Yang, Q., Qiao, S., Wu, Z., & Han, W. (2021). Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial. Leukemia, 1–8. https://doi.org/10.1038/s41375-021-01345-8 Cite
